Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.
Xeno Biosciences has raised $1.5M in total funding. The most recent round was Debt Financing. The last funding was announced in January 2023.
Xeno Biosciences's investors include Maine Angels, ScOp Venture Capital, Dirigo Angels, Bantam Group, Keiretsu Forum.
Xeno Biosciences is headquartered in Somerville, United States.
Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.
Xeno Biosciences is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Xeno Biosciences — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/xeno-biosciences. Accessed September 30, 2026.
VCBacked. (2023). Xeno Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/xeno-biosciences
{{cite web |title=Xeno Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/xeno-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated